Marcelo Bigal

Santa Ana Bio leverages deep cell profiling technologies, to design precision biologics in the innate immunity space.

Responsible for general medical governance and patient safety oversight relating to all Purdue products, as well as of its subsidiaries, in development and in the market.

Leading all specialty research and development, including discovery, early and late stage clinical development, safety and pharmacovigilance, as well setting scientific priorities for the specialty pipeline.

Head of a group with over 600 employees, in charge of Global Early Stage Clinical Development, Global Late Stage Clinical Development, Global Safety and Pharmacovigilance and Global and Regional Clinical Operations, Biometrics and Data Management. Reports to the President of Global R&D.

Responsible for directing and leading the Clinical Development (Phases 1 to 3),across all specialty areas at Teva. Areas include Migraine/Headaches, Pain, Neurodegeneration, Movement Disorders, Multiple Sclerosis, Respiratory, and others. Responsible for leading the Clinical Pharmacology, Global Clinical Operations and Biometrics groups as well. Reports to the President, Global R&D.

Head of R&D group housing Global Clinical Operations, Clinical Pharmacology, Global Biometrics and Global Medical Writing. Therapeutic Area head for the Migraine and Headache programs.

Responsible for all R&D activities required to support the development of medications in migraine and pain, including the development of LBR-101, a monoclonal antibody against CGRP, and of Zecuity, the novel iontophoretic patch for the acute treatment of migraine. Also responsible for providing key strategic input to any further business development activities the company in this field.

Responsible for heading the research development of a humanized monoclonal antibody targeting CGRP, a molecule of relevance in migraine and pain. Direct reports include Head of Preclinical Research, VP of Clinical Operations and VP of Regulatory Affairs.

* Head of an organization that encompassed 13 research committees and is responsible for the review of over 1300 research proposals per year, and for the funding of over 400 studies per year across all therapeutic areas of interest to Merck. The division also reviews company initiated non-regulatory studies globally. Department consists of nearly 40 employees/contractors * Head of scientific education, or the development of unbranded curriculum on drug development for use at academic institutions. * Manager of 5 M.D. Global Executive Directors covering scientific affairs in the areas of HIV, Hepatitis, Anti-Infectious diseases, Ophthalmology, Anesthesiology, and Oncology.

Responsible for scientific and medical affairs in neurology and psychiatry. Developed the scientific leadership strategy for both areas at Merck (including chairing investigator initiated study programs, running advisory boards)

Responsible for the execution of clinical trials (phase 1 to 3), as well as for the development and funding of investigator initiated studies. Over 30 studies conducted during tenure.

Dissertation in the field of neuroepidemiology. Thesis was a clinical trial on the IV treatment of migraine.

Dissertation on the economic impact of migraine to a public hospital.